Physician profile
Sarah E Wiegand
NPI 1164818035
$1,613.68
in general payments reported to CMS, 2019-2025
18 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $104 · 2021: $140 · 2022: $45.53 · 2023: $323 · 2024: $605 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $368.37 | 2022-2025 | Valtoco |
| Ucb, INC. | $273.83 | 2023-2025 | Briviact, Fintepla |
| Jazz Pharmaceuticals INC. | $145.62 | 2023-2024 | |
| Catalyst Pharmaceuticals, INC. | $128.41 | 2023-2025 | Fycompa |
| Greenwich Biosciences, INC. | $119.46 | 2021 | |
| Immedica Pharma US, INC. | $114.40 | 2023-2024 | |
| Livanova USA, INC. | $103.59 | 2020 | |
| Acadia Pharmaceuticals INC | $93.70 | 2023-2025 | Daybue |
| Upsher-Smith Laboratories LLC | $57.53 | 2023-2025 | |
| Pyros Pharmaceuticals, INC. | $53.60 | 2024 | Vigpoder |
| Ns Pharma, INC. | $23.11 | 2023 | Viltepso |
| Aquestive Therapeutics, INC. | $22.41 | 2022 | |
| Azurity Pharmaceuticals, INC. | $21.15 | 2023 | Eprontia |
| Eisai INC. | $20.30 | 2021 | |
| Biocodex, INC. | $19.36 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $17.72 | 2024 | |
| Aucta Pharmaceuticals, INC. | $16.60 | 2025 | Motpoly Xr |
| Biomarin Pharmaceutical INC. | $14.52 | 2023 | Brineura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Wiegand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.